US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Avalyn Pharma Inc. priced above expectations and surged 44% at open, closing up ~64% in a strong first-day performance.</li>
<li>Upsized deal and multiple-times oversubscribed book reflect high-quality institutional demand and strong biotech sector momentum.</li>
<li>Marks a positive inflection for pulmonary fibrosis IPOs after prior underperformance, signaling improving investor sentiment in the subsector.</li>
</ul>


Avalyn Pharma Inc. priced above expectations and surged 44% at open, closing up ~64% in a strong first-day performance.
Upsized deal and multiple-times oversubscribed book reflect high-quality institutional demand and strong biotech sector momentum.
Marks a positive inflection for pulmonary fibrosis IPOs after prior underperformance, signaling improving investor sentiment in the subsector.


Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✅ IPO PROPHET RATING: 7.61/10 🏦 Deal Quality &amp; Underwriters: 8.3/10 Avalyn Pharma is coming to market offering approximately 11.8 million shares at $16 to $18, targeting roughly $200 million in proceeds.</li><li>The company is focused on inhaled therapies for pulmonary diseases, including treatments for rare and chronic respiratory conditions.</li><li>The deal is being marketed to healthcare-focused institutional investors within an active but selective biotech IPO environment.</li></ul>

✅ IPO PROPHET RATING: 7.61/10 🏦 Deal Quality &amp; Underwriters: 8.3/10 Avalyn Pharma is coming to market offering approximately 11.8 million shares at $16 to $18, targeting roughly $200 million in proceeds.The company is focused on inhaled therapies for pulmonary diseases, including treatments for rare and chronic respiratory conditions.The deal is being marketed to healthcare-focused institutional investors within an active but selective biotech IPO environment.

<ul><li>Avalyn Pharma Inc. (Nasdaq: AVLN) has filed to raise approximately $200 million in its upcoming IPO, offering 11.8 million shares at a price range of $16 to $18 , implying a midpoint deal size of roughly $200.6 million.</li><li>At the midpoint price of $17 , the company is expected to command a market capitalization of approximately $628 million based on 36.9 million shares outstanding post-offering.</li><li>The deal is being led by Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities, with shares expected to list on the Nasdaq Global Market under the ticker AVLN.</li></ul>

Avalyn Pharma Inc. (Nasdaq: AVLN) has filed to raise approximately $200 million in its upcoming IPO, offering 11.8 million shares at a price range of $16 to $18 , implying a midpoint deal size of roughly $200.6 million.At the midpoint price of $17 , the company is expected to command a market capitalization of approximately $628 million based on 36.9 million shares outstanding post-offering.The deal is being led by Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities, with shares expected to list on the Nasdaq Global Market under the ticker AVLN.

Avalyn Pharma Sets Terms for ~$200M IPO as Inhaled Pulmonary Fibrosis Platform

<ul>
<li>Lead pipeline targets pulmonary fibrosis via inhaled antifibrotics, aiming to improve efficacy and reduce systemic side effects versus oral therapies.</li>
<li>Backed by top-tier investors including Novo Holdings A/S and led by experienced CEO Lyn Baranowski.</li>
<li>Avalyn Pharma Inc. IPO reportedly multiple-times oversubscribed, with books closing Tuesday ahead of expected Thursday debut.</li>
</ul>


Lead pipeline targets pulmonary fibrosis via inhaled antifibrotics, aiming to improve efficacy and reduce systemic side effects versus oral therapies.
Backed by top-tier investors including Novo Holdings A/S and led by experienced CEO Lyn Baranowski.
Avalyn Pharma Inc. IPO reportedly multiple-times oversubscribed, with books closing Tuesday ahead of expected Thursday debut.


Avalyn Pharma (AVLN): Pulmonary Fibrosis IPO Drawing Strong Demand Despite Comp Underperformance

<ul>
<li>Avalyn Pharma Inc. prices IPO at $16–$18/share, offering 11.8M shares to fund inhaled fibrosis therapies, targeting ~$591M–$665M valuation.</li>
<li>Clinical-Stage pipeline led by AP01 and AP02 aims to treat IPF and PPF via inhaled antifibrotics, addressing high unmet need in interstitial lung disease.</li>
<li>Backed by top-tier underwriters including Morgan Stanley and Jefferies; CEO Lyn Baranowski brings deep respiratory biotech experience and strong M&amp;A track record.</li>
</ul>


Avalyn Pharma Inc. prices IPO at $16–$18/share, offering 11.8M shares to fund inhaled fibrosis therapies, targeting ~$591M–$665M valuation.
Clinical-Stage pipeline led by AP01 and AP02 aims to treat IPF and PPF via inhaled antifibrotics, addressing high unmet need in interstitial lung disease.
Backed by top-tier underwriters including Morgan Stanley and Jefferies; CEO Lyn Baranowski brings deep respiratory biotech experience and strong M&amp;A track record.


Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

United States

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops inhaled medicines to treat respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Avalyn Pharma operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avalyn Pharma (AVLN US)

Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO

Avalyn Pharma Inc. IPO exceeds expectations, surges 64% in strong debut, reflecting high institutional demand and improving investor sentiment in...

IPO Boutique

IPO Rating: Avalyn Pharma Inc.

✅ IPO PROPHET RATING: 7.61/10 🏦 Deal Quality & Underwriters: 8.3/10 Avalyn Pharma is coming to market offering approximately 11.8 million...

IPO Prophet

Avalyn Pharma Sets Terms for ~$200M IPO as Inhaled Pulmonary Fibrosis Platform

Avalyn Pharma Inc. (Nasdaq: AVLN) has filed to raise approximately $200 million in its upcoming IPO, offering 11.8 million shares at a price range...

IPO Prophet

Avalyn Pharma (AVLN): Pulmonary Fibrosis IPO Drawing Strong Demand Despite Comp Underperformance

Avalyn Pharma Inc. aims to revolutionize pulmonary fibrosis treatment with inhaled antifibrotics, backed by top investors and oversubscribed IPO.

IPO Boutique

Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO

​Avalyn Pharma Inc. IPO exceeds expectations, surges 64% in strong debut, reflecting high institutional demand and improving investor sentiment in...

IPO Boutique

IPO Rating: Avalyn Pharma Inc.

✅ IPO PROPHET RATING: 7.61/10 🏦 Deal Quality & Underwriters: 8.3/10 Avalyn Pharma is coming to market offering approximately 11.8 million...

IPO Prophet

Avalyn Pharma Sets Terms for ~$200M IPO as Inhaled Pulmonary Fibrosis Platform

Avalyn Pharma Inc. (Nasdaq: AVLN) has filed to raise approximately $200 million in its upcoming IPO, offering 11.8 million shares at a price range...

IPO Prophet

Avalyn Pharma (AVLN): Pulmonary Fibrosis IPO Drawing Strong Demand Despite Comp Underperformance

​Avalyn Pharma Inc. aims to revolutionize pulmonary fibrosis treatment with inhaled antifibrotics, backed by top investors and oversubscribed IPO.

IPO Boutique

Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

​Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...

IPO Boutique

Avalyn Pharma Inc. IPO exceeds expectations, surges 64% in strong debut, reflecting high institutional demand and improving investor sentiment in...

Avalyn Pharma Inc. aims to revolutionize pulmonary fibrosis treatment with inhaled antifibrotics, backed by top investors and oversubscribed IPO.

Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...